Premafloxacin
Premafloxacin is a potent antimicrobial agent that exhibits activity against Staphylococcus aureus, Corynebacterium bovis, and Corynebacterium amylocolatum. Premafloxacin demonstrated potent antimicrobial activity against S. aureus by targeting topoisomerase IV, and is a poor substrate for NorA efflux pump. Premafloxacin can be used for antimicrobial research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 143383-65-7
- 分子式: C21H26FN3O4
- 分子量:403.45
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Topoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
TOPO IV |
体外実験
Premafloxacin (24-48 h) exhibits activity against wild-type S. aureus ISP794 with MIC of 0.004-0.008 μg/mL, while showing 4- to 8-fold decreased activity against various grlA and grlB mutants of these two strains with altered subunits of topoisomrase IV (MIC: 0.032-0.064 μg/mL)[1].
Premafloxacin (2-8× MIC; 48 h) fails to select for resistant single-step mutants of S. aureus ISP794 at 4 × or higher MICs, with resistant mutants only detectable at 2× MIC (mutation frequency: 6.4×10-10 to 4.0×10-7)[1].
Premafloxacin (24 h) exhibits potent in vitro activity against both Corynebacterium bovis and Corynebacterium amylocolatum strains isolated from bovine mammary glands, with MIC90s of 0.015 μg/mL[2].
Premafloxacin (24-48 h) exhibits a 2-fold decreased activity against flqB mutant, which overexpresses NorA efflux pump, indicating that it is a poor substrate for NorA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 143383-65-7
-
分子量 403.45
-
分子式 C21H26FN3O4
-
SMILES
O(C)C1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@]([C@@H](NC)C)(CC3)[H])C4CC4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Ince D, et al. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother. 2000;44(12):3344-3350. [Content Brief]
[2]. Watts JL, et al. Susceptibilities of Corynebacterium bovis and Corynebacterium amylocolatum isolates from bovine mammary glands to 15 antimicrobial agents. Antimicrob Agents Chemother. 2000;44(12):3476-3477. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Premafloxacin 関連分類
HY-180414 関連分類
Powered by Bioz